What Happened
Eli Lilly has registered two global Phase 3 trials for EloraTZP, its combination of the selective amylin agonist eloralintide and the dual GIP/GLP-1 agonist tirzepatide. The studies, designated AMPLIFY-1 and AMPLIFY-2, together plan to enroll roughly 3,115 patients, stratified by whether they have type 2 diabetes, and both list a primary completion target in November 2029.
The registration formally opens late-stage development for a regimen Lilly has positioned as a successor to tirzepatide and its triple agonist retatrutide. In the Phase 2 trial reported last month, the highest-dose combination arm produced average weight loss of 23.3% at 48 weeks against 14.8% for tirzepatide alone in adults with obesity or overweight and type 2 diabetes. A1C fell by up to 2.9 percentage points on the combination versus 2.4 on tirzepatide alone.
The caveats were equally prominent. Each arm held roughly 37 patients, the weight-loss figures assumed continued treatment, and discontinuation due to adverse events ranged from 10.8% to 27.0% across combination arms — against 2.9% for tirzepatide monotherapy. Most events were gastrointestinal and described as mild to moderate, clustering during dose escalation.
Lilly's answer is titration: adverse events concentrated in escalation, and Phase 3 will use a refined schedule trading a slower ramp for persistence.
Who Is Affected
- Adults with obesity and type 2 diabetes, the population the Phase 3 program will enroll and the group with the most to gain from a combination that outperforms tirzepatide alone.
- The amylin class as a whole, including Novo Nordisk's CagriSema, which pairs cagrilintide with semaglutide and is already under U.S. regulatory review.
- Korean and Asian developers, where Celltrion's CT-G32, a quadruple agonist spanning amylin, GLP-1, GIP, and glucagon receptors, is in early clinical work with preclinical data expected in November.
Timeline
- September 30, 2026: Phase 2 combination data presented at the European Association for the Study of Diabetes annual meeting.
- October 2026: AMPLIFY-1 and AMPLIFY-2 registered on the U.S. clinical trial registry.
- 2027-2029: Enrollment and follow-up across both trials.
- November 2029: Primary completion target for both studies.
What This Means for Researchers
Tolerability has become the competitive metric in obesity drug development, and the Phase 3 design makes that explicit. A regimen that delivers 23% weight loss but loses one patient in four to gastrointestinal effects will struggle in real-world use, where persistence drives outcomes more than peak efficacy.
The second point is methodological. Phase 2 signals from arms of roughly 37 participants are directionally useful and statistically fragile. The 2.9-point A1C change and the 23.3% weight-loss figure both need confirmation in a program sized to detect differences in discontinuation, not just in weight.
Third, amylin agonism is no longer speculative. Amylin alone, amylin plus incretin, and multi-agonist constructs are all in or near late-stage testing.
How to Verify Your Peptides
If you are working with research-grade material rather than an approved product, documentation matters more than any pipeline headline. Review how our testing works and the distinction between identity testing and purity testing. Amylin analogs and incretin peptides are frequently misidentified in gray-market supply, and only independent analysis resolves that.
Safe Alternatives
Approved incretin therapies remain the reference standard: see our compound pages for tirzepatide, semaglutide, and retatrutide, or browse tested suppliers in the vendor directory. The peptide library covers the underlying literature.
Sources
Clinical trial registry entries; company statements; industry reports.